Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

Wave Life Sciences Ltd.
Next earnings Jul 28, 2026 · consensus $-0.31 EPS, $7.12M rev
Last earnings +8.4% on 2026-04-28
Conservative balance sheet (liabilities/equity 0.22x); but revenue fell -60.5% YoY.
Wave Life Sciences Ltd. shows $42.7M in FY2025 revenue (-60.5% YoY), a -478.3% net margin, and -39.4% ROE.
Sources: SEC EDGAR (CIK 0001631574, latest 10-Q filed 2026-04-28) · EODHD · as of 6/22/2026, 1:42:56 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $41.0M | $3.65M | $113M | $108M | $42.7M |
| Gross profit | — | — | — | — | — |
| Operating income | -$127M | -$163M | -$68.0M | -$110M | -$215M |
| Net income | -$122M | -$162M | -$57.5M | -$97.0M | -$204M |
| Diluted EPS | -$2.36 | -$2.05 | -$0.54 | -$0.70 | -$1.21 |
| Net margin | -298.4% | -4434.7% | -50.8% | -89.6% | -478.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 4 open-market buys · 0 sales
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. Director | Buy | 971K @ $6.50 | $6.31M |
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P. Director | Buy | 2.50M @ $6.43 | $16.0M |
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P. Director | Buy | 4.95M @ $6.06 | $30.0M |
| 2026-03-26 | RA CAPITAL MANAGEMENT, L.P. Director | Buy | 351K @ $6.38 | $2.24M |
| 2026-03-23 | TAKANASHI KEN Director | Acquired (C) | 3.90M | |
| 2026-02-26 | Francis Chris See Remarks | Exercise | 17.9K @ $3.87 | $69.3K |
| 2026-02-26 | Francis Chris See Remarks | Sell | 17.9K @ $15.09 | $270K |
| 2026-02-26 | Francis Chris See Remarks | Exercise | 15.3K @ $4.75 | $72.6K |
| 2026-02-26 | Francis Chris See Remarks | Sell | 15.3K @ $15.00 | $229K |
| 2026-02-09 | Moran Kyle Chief Financial Officer | Sell | 3.59K @ $13.45 | $48.3K |
| 2026-02-09 | BOLNO PAUL President and CEO | Sell | 10.5K @ $13.45 | $141K |
| 2026-02-09 | Francis Chris See Remarks | Sell | 1.88K @ $13.45 | $25.3K |